Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy
Objective: Systemic anaplastic large cell lymphoma (sALCL) is a rare and severe non-Hodgkin lymphoma. Despite its clinical relevance, the aetiology of this disease is unknown, not allowing the patient to prevent and counteract it. This study investigates the cost-effectiveness of Brentuximab Vedoti...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2025-04-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/3306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850281756279701504 |
|---|---|
| author | Andrea Marcellusi Chiara Bini Laura Fioravanti Silvia Ripoli Paolo Morelli |
| author_facet | Andrea Marcellusi Chiara Bini Laura Fioravanti Silvia Ripoli Paolo Morelli |
| author_sort | Andrea Marcellusi |
| collection | DOAJ |
| description |
Objective: Systemic anaplastic large cell lymphoma (sALCL) is a rare and severe non-Hodgkin lymphoma. Despite
its clinical relevance, the aetiology of this disease is unknown, not allowing the patient to prevent and counteract
it. This study investigates the cost-effectiveness of Brentuximab Vedotin (BV) in combination with cyclophosphamide,
doxorubicin and prednisone (CHP) for the front-line treatment of patients with sALCL in Italy.
Methods: The analysis was conducted from the perspective of the National Health Service using a three-state
partitioned survival model with cycles lasting 21 days and a lifetime time horizon. The survival curves were taken
from three-year follow-up data of ECHELON-2 trial. Costs were obtained from published literature and national
tariffs. For all drugs, ex-factory prices net of the mandatory reductions required by law were considered.
Results: Compared with CHOP, BV in combination with CHP was associated with an increase of € 46,349 total
costs, 2.3 life years and 1.8 quality-adjusted life-years (QALYs) respectively. The incremental cost-utility ratios
(ICUR) were estimated equal to € 25,367/QALY compared with CHOP, resulting below the value of € 41,411/QALY
for severe diseases in Italy.
Conclusions: Based on data from 3 years of follow-up from the ECHELON-2 trial, BV in combination with CHP is
estimated a cost-effective option versus CHOP for the front-line treatment of sALCL in Italy. Data from 5-year from
the ECHELON-2 trial confirmed the advantage in terms of PFS and OS. The analysis also suggested that treatment
with BV+CHP may be cost-effective compared with CHOEP.
|
| format | Article |
| id | doaj-art-5055e138d3c74606a9ed1ef82f572df3 |
| institution | OA Journals |
| issn | 2284-2403 2283-5733 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj-art-5055e138d3c74606a9ed1ef82f572df32025-08-20T01:48:11ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332025-04-0112110.33393/grhta.2025.3306Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in ItalyAndrea Marcellusi0Chiara Bini1Laura Fioravanti2Silvia Ripoli3Paolo Morelli4Department of Pharmaceutical Sciences – DISFARM, University of Milan, Milan - ItalyFaculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome “Tor Vergata”, Rome - ItalyPatient Value & Access Department, Takeda Italia S.p.A., Rome - ItalyPatient Value & Access Department, Takeda Italia S.p.A., Rome - ItalyMedical Department, Takeda Italia S.p.A., Rome - Italy Objective: Systemic anaplastic large cell lymphoma (sALCL) is a rare and severe non-Hodgkin lymphoma. Despite its clinical relevance, the aetiology of this disease is unknown, not allowing the patient to prevent and counteract it. This study investigates the cost-effectiveness of Brentuximab Vedotin (BV) in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for the front-line treatment of patients with sALCL in Italy. Methods: The analysis was conducted from the perspective of the National Health Service using a three-state partitioned survival model with cycles lasting 21 days and a lifetime time horizon. The survival curves were taken from three-year follow-up data of ECHELON-2 trial. Costs were obtained from published literature and national tariffs. For all drugs, ex-factory prices net of the mandatory reductions required by law were considered. Results: Compared with CHOP, BV in combination with CHP was associated with an increase of € 46,349 total costs, 2.3 life years and 1.8 quality-adjusted life-years (QALYs) respectively. The incremental cost-utility ratios (ICUR) were estimated equal to € 25,367/QALY compared with CHOP, resulting below the value of € 41,411/QALY for severe diseases in Italy. Conclusions: Based on data from 3 years of follow-up from the ECHELON-2 trial, BV in combination with CHP is estimated a cost-effective option versus CHOP for the front-line treatment of sALCL in Italy. Data from 5-year from the ECHELON-2 trial confirmed the advantage in terms of PFS and OS. The analysis also suggested that treatment with BV+CHP may be cost-effective compared with CHOEP. https://journals.aboutscience.eu/index.php/grhta/article/view/3306Brentuximab VedotinCost-effectiveness analysiseconomic evaluationsALCLSystemic anaplastic large cell lymphoma |
| spellingShingle | Andrea Marcellusi Chiara Bini Laura Fioravanti Silvia Ripoli Paolo Morelli Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy Global & Regional Health Technology Assessment Brentuximab Vedotin Cost-effectiveness analysis economic evaluation sALCL Systemic anaplastic large cell lymphoma |
| title | Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy |
| title_full | Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy |
| title_fullStr | Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy |
| title_full_unstemmed | Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy |
| title_short | Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy |
| title_sort | cost effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in italy |
| topic | Brentuximab Vedotin Cost-effectiveness analysis economic evaluation sALCL Systemic anaplastic large cell lymphoma |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/3306 |
| work_keys_str_mv | AT andreamarcellusi costeffectivenessofbrentuximabvedotinpluschemotherapyasfrontlinetreatmentofsystemicanaplasticlargecelllymphomainitaly AT chiarabini costeffectivenessofbrentuximabvedotinpluschemotherapyasfrontlinetreatmentofsystemicanaplasticlargecelllymphomainitaly AT laurafioravanti costeffectivenessofbrentuximabvedotinpluschemotherapyasfrontlinetreatmentofsystemicanaplasticlargecelllymphomainitaly AT silviaripoli costeffectivenessofbrentuximabvedotinpluschemotherapyasfrontlinetreatmentofsystemicanaplasticlargecelllymphomainitaly AT paolomorelli costeffectivenessofbrentuximabvedotinpluschemotherapyasfrontlinetreatmentofsystemicanaplasticlargecelllymphomainitaly |